Business
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategyWESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlight
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"Turn Therapeutics","displaySize":"","headline":null,"caption":"Turn Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uTv2v5jICXhGET5aPRSD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39","width":300,"height":101}},"lazy":false},{"type":"text","content":"Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy","length":146,"tagName":"p"},{"type":"text","content":"WESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following its dilution-sparing direct listing.","length":446,"tagName":"p"},{"type":"text","content":"Capital Strategy and AlignmentTurn chose a direct listing structure to prioritize flexibility and long-term shareholder alignment. By bypassing traditional crossover rounds and IPO share issuance, early shareholders maintained their ownership positions.","length":254,"tagName":"p"},{"type":"text","content":"Through its $85 million GEM Global Yield agreement, the Company entered the market with a flexible, on-demand financing vehicle in place. This structure allows Turn to access capital opportunistically, at times and amounts determined by the Company, and eliminated the need for a traditional offering at the time of listing. It also provides the potential to reduce reliance on future equity offerings.","length":407,"tagName":"p"},{"type":"text","content":"Pipeline and Development UpdateTurn continues to advance its phase 2, randomized, double-blind, placebo-controlled trial of GX-03 as a potential treatment for moderate to severe eczema. As of now, approximately 25% of the targeted sample size has completed the trial with ongoing enrollment continuing.","length":303,"tagName":"p"},{"type":"text","content":"This study...